{
    "clinical_study": {
        "@rank": "154537", 
        "arm_group": {
            "arm_group_label": "RO5072759 [GA101]", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and\n      safety of RO5072759 (GA101) in patients with CD20+ malignant lymphoma. Patients will receive\n      multiple doses of RO5072759 (GA101). The anticipated time on study treatment is 24 weeks."
        }, 
        "brief_title": "A Study of RO5072759 (GA101) in Patients With CD20+-Malignant Lymphoma", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphocytic Leukemia, Chronic, Lymphoma, B-Cell, Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell", 
                "Chronic Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >18 years of age\n\n          -  Diagnosis of CD20+ B-cell lymphoma, chronic lymphocytic lymphoma (CLL), or follicular\n             lymphoma (FL)\n\n          -  Refractory/relapsed CLL, FL, and diffuse large B cell lymphoma (DLBCL)\n\n          -  Measurable lesion (>1.5cm in its largest dimension) with the exception of CLL\n\n          -  Eastern Cooperative Oncology Group performance status of 0 or 1\n\n          -  Life expectancy over 6 months\n\n        Exclusion Criteria:\n\n          -  Prior use of any investigational antibody therapy within 6 months of study start\n\n          -  Prior use of any anti-cancer vaccines\n\n          -  Prior administration of rituximab within 3 months of study start\n\n          -  Central nervous system lymphoma\n\n          -  History of other malignancy\n\n          -  Evidence of significant, uncontrolled concomitant disease\n\n          -  Abnormal laboratory values\n\n          -  Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01680991", 
            "org_study_id": "YP25623"
        }, 
        "intervention": {
            "arm_group_label": "RO5072759 [GA101]", 
            "description": "multiple doses of RO5072759 [GA101]", 
            "intervention_name": "RO5072759 [GA101]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100021"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100142"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510080"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200025"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "zip": "300020"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Open Label, Single Arm, Multiple Dose Study to Assess the Pharmacokinetics of RO5072759 in Chinese Patients With CD20+ Malignant Disease.", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetics: Serum concentration of RO5072759 (GA101)", 
            "safety_issue": "No", 
            "time_frame": "Predose, Cycle 1, Day 1, 8, 15; Cycles 2-8; Follow up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01680991"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Treatment response according to criteria for evaluation of response in Non-Hodgkin's-Lymphoma", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Pharmacodynamics: B19+B-cell measurement", 
                "safety_issue": "No", 
                "time_frame": "Predose, Cycle 1: Day 1, 8; Cycles 2, 4, 6, 8; Follow up"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}